Denmark's Ferring Pharmaceuticals has concluded a deal with Swiss health care major Novartis for the acquisition of the worldwide manufacturing, marketing and distribution rights to Norprolac (quinagolide). No financial terms of the accord were disclosed.
The agent is a prolactin inhibitor indicated for the management of hyperprolactinemia, a disorder that suppresses ovulation by the production of excess levels of the hormone prolactin, and is a major cause of female infertility. Norprolac is ranked fourth in terms of sales in this disease area, behind Pfizer's cabergoline, Novartis' bromocriptine and Nihon-Schering's terguride, noted Ferring.
The deal will allow Ferring to further expand and diversify its infertility portfolio, which makes up more than one third of its total sales revenue. The firm's other products in this therapeutic area include:
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze